1887

Abstract

Ultra-deep pyrosequencing (UDPS) was used to analyse the dynamics of quasispecies and resistant mutations during telbivudine (LDT) treatment of hepatitis B patients. Twenty-six HBeAg-positive chronic hepatitis B patients were treated with LDT for a period of 104 weeks and were characterized as 16 responders, six partial responders and four viral breakthrough patients based on hepatitis B virus (HBV) DNA levels. The plasma samples were subjected to UDPS of the reverse transcriptase (RT) region of HBV. Mutations rtM204I, rtL80I and rtL80V were detected in at least three of the four viral breakthrough patients, indicating the significant roles of the mutations in resistance to LDT. The degree of complexity of viral quasispecies remained in a steady state in the absence of selection pressure, but increased after the LDT treatment. The complexity in the responder group at week 12 was significantly higher than that in the group comprising partial responders and viral breakthrough patients. replication efficiency analyses showed that the RT mutations had different impacts on HBV replication, with a tendency of rtM204I>rtL80V>rtL80I. Furthermore, double mutations rtL80I/M204I and rtL80V/M204V had replication efficiency similar to that of rtL80I and rtL80V, respectively. Consistent with previous studies, mutation rtM204I was found to be highly resistant to LDT. However, in contrast with their sensitivity to lamivudine, rtL80I and rtL80V were moderately resistant to LDT. Our results indicated that rtL80I and rtL80V may not only serve as replication complementary mutations to rtM204I, but also directly contribute to the LDT resistance.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000285
2015-11-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/11/3302.html?itemId=/content/journal/jgv/10.1099/jgv.0.000285&mimeType=html&fmt=ahah

References

  1. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.-A., Tyrrell D.L., Brown N., Condreay L.D., Lamivudine Clinical Investigation Group. ( 1998;). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27: 1670–1677 [CrossRef] [PubMed].
    [Google Scholar]
  2. Cao L., Wu C., Shi H., Gong Z., Zhang E., Wang H., Zhao K., Liu S., Li S., other authors. ( 2014;). Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses. J Virol 88: 8656–8666 [CrossRef] [PubMed].
    [Google Scholar]
  3. Chen L., Zhang Q., Yu D.M., Wan M.B., Zhang X.X.. ( 2009;). Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol 50: 895–905 [CrossRef] [PubMed].
    [Google Scholar]
  4. Ciftci S., Keskin F., Cakiris A., Akyuz F., Pinarbasi B., Abaci N., Dincer E., Badur S., Kaymakoglu S., Ustek D.. ( 2014;). Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method. Diagn Microbiol Infect Dis 79: 25–30 [CrossRef] [PubMed].
    [Google Scholar]
  5. Clavel F., Hance A.J.. ( 2004;). HIV drug resistance. N Engl J Med 350: 1023–1035 [CrossRef] [PubMed].
    [Google Scholar]
  6. de la Torre J.C., Holland J.J.. ( 1990;). RNA virus quasispecies populations can suppress vastly superior mutant progeny. J Virol 64: 6278–6281 [PubMed].
    [Google Scholar]
  7. Delaney W.E. IV, Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., Miller M.D., Xiong S.. ( 2003;). The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77: 11833–11841 [CrossRef] [PubMed].
    [Google Scholar]
  8. Dienstag J.L.. ( 2008;). Hepatitis B virus infection. N Engl J Med 359: 1486–1500 [CrossRef] [PubMed].
    [Google Scholar]
  9. Domingo E., Gomez J.. ( 2007;). Quasispecies and its impact on viral hepatitis. Virus Res 127: 131–150 [CrossRef] [PubMed].
    [Google Scholar]
  10. Domingo E., Escarmis C., Martinez M.A., Martinez-Salas E., Mateu M.G.. ( 1992;). Foot-and-mouth disease virus populations are quasispecies. Curr Top Microbiol Immunol 176: 33–47 [PubMed].
    [Google Scholar]
  11. Domingo E., Martín V., Perales C., Grande-Pérez A., García-Arriaza J., Arias A.. ( 2006;). Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol 299: 51–82 [PubMed].
    [Google Scholar]
  12. Eriksson N., Pachter L., Mitsuya Y., Rhee S.Y., Wang C., Gharizadeh B., Ronaghi M., Shafer R.W., Beerenwinkel N.. ( 2008;). Viral population estimation using pyrosequencing. PLOS Comput Biol 4: e1000074 [CrossRef] [PubMed].
    [Google Scholar]
  13. Fishman S.L., Branch A.D.. ( 2009;). The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol 9: 1158–1167 [CrossRef] [PubMed].
    [Google Scholar]
  14. Forns X., Purcell R.H., Bukh J.. ( 1999;). Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 7: 402–410 [CrossRef] [PubMed].
    [Google Scholar]
  15. Hedskog C., Mild M., Jernberg J., Sherwood E., Bratt G., Leitner T., Lundeberg J., Andersson B., Albert J.. ( 2010;). Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5: e11345 [CrossRef] [PubMed].
    [Google Scholar]
  16. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., Pease L.R.. ( 1989;). Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51–59 [CrossRef] [PubMed].
    [Google Scholar]
  17. Jiang L., Shi J., Liu Y., Liu W., Si L., Zhong Y., Xu D.. ( 2010;). Efficient replication and expression of a 1.1-ploid genome length HBV recombinant plasmid vector in Huh7 cells. Med J Chinese People's Liberation Army 35: 635–638.
    [Google Scholar]
  18. Kwon H., Lok A.S.. ( 2011;). Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8: 275–284 [PubMed].
    [Google Scholar]
  19. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., other authors. ( 2007;). Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357: 2576–2588 [CrossRef] [PubMed].
    [Google Scholar]
  20. Lavanchy D.. ( 2004;). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97–107 [CrossRef] [PubMed].
    [Google Scholar]
  21. Le T., Chiarella J., Simen B.B., Hanczaruk B., Egholm M., Landry M.L., Dieckhaus K., Rosen M.I., Kozal M.J.. ( 2009;). Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 4: e6079 [CrossRef] [PubMed].
    [Google Scholar]
  22. Ling R., Harrison T.J.. ( 1999;). Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 80: 601–606 [CrossRef] [PubMed].
    [Google Scholar]
  23. Liu F., Chen L., Yu D.M., Deng L., Chen R., Jiang Y., Chen L., Huang S.Y., Yu J.L., other authors. ( 2011;). Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut 60: 1269–1277 [CrossRef] [PubMed].
    [Google Scholar]
  24. Locarnini S.. ( 2008;). Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2: 147–151 [CrossRef] [PubMed].
    [Google Scholar]
  25. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.-M., Liaw Y.-F., Mizokami M., Kuiken C., Hepatitis B Virus Drug Resistance Working Group. ( 2007;). Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46: 254–265 [CrossRef] [PubMed].
    [Google Scholar]
  26. Margeridon-Thermet S., Shulman N.S., Ahmed A., Shahriar R., Liu T., Wang C., Holmes S.P., Babrzadeh F., Gharizadeh B., other authors. ( 2009;). Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199: 1275–1285 [CrossRef] [PubMed].
    [Google Scholar]
  27. Matthews S.J.. ( 2007;). Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 29: 2635–2653 [CrossRef] [PubMed].
    [Google Scholar]
  28. Nash K.. ( 2009;). Telbivudine in the treatment of chronic hepatitis B. Adv Ther 26: 155–169 [CrossRef] [PubMed].
    [Google Scholar]
  29. Ngui S.L., Teo C.G.. ( 1997;). Hepatitis B virus genomic heterogeneity: variation between quasispecies may confound molecular epidemiological analyses of transmission incidents. J Viral Hepat 4: 309–315 [CrossRef] [PubMed].
    [Google Scholar]
  30. Nishijima N., Marusawa H., Ueda Y., Takahashi K., Nasu A., Osaki Y., Kou T., Yazumi S., Fujiwara T., other authors. ( 2012;). Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One 7: e35052 [CrossRef] [PubMed].
    [Google Scholar]
  31. Ono S.K., Kato N., Shiratori Y., Kato J., Goto T., Schinazi R.F., Carrilho F.J., Omata M.. ( 2001;). The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107: 449–455 [CrossRef] [PubMed].
    [Google Scholar]
  32. Pallier C., Castéra L., Soulier A., Hézode C., Nordmann P., Dhumeaux D., Pawlotsky J.-M.. ( 2006;). Dynamics of hepatitis B virus resistance to lamivudine. J Virol 80: 643–653 [CrossRef] [PubMed].
    [Google Scholar]
  33. Ramírez C., Gregori J., Buti M., Tabernero D., Camós S., Casillas R., Quer J., Esteban R., Homs M., Rodriguez-Frías F.. ( 2013;). A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Antiviral Res 98: 273–283 [CrossRef] [PubMed].
    [Google Scholar]
  34. Rhee S.Y., Margeridon-Thermet S., Nguyen M.H., Liu T.F., Kagan R.M., Beggel B., Verheyen J., Kaiser R., Shafer R.W.. ( 2010;). Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res 88: 269–275 [CrossRef] [PubMed].
    [Google Scholar]
  35. Rodriguez C., Chevaliez S., Bensadoun P., Pawlotsky J.-M.. ( 2013;). Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 58: 890–901 [CrossRef] [PubMed].
    [Google Scholar]
  36. Schmidt-Martin D., Crosbie O., Kenny-Walsh E., Fanning L.J.. ( 2012;). Hepatitis C quasispecies adaptation in the setting of a variable fidelity polymerase. Virus Adaptation Treatment 4: 43–50 [CrossRef].
    [Google Scholar]
  37. Sheldon J., Soriano V.. ( 2008;). Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 61: 766–768 [CrossRef] [PubMed].
    [Google Scholar]
  38. Sloan R.D., Ijaz S., Moore P.L., Harrison T.J., Teo C.-G., Tedder R.S.. ( 2008;). Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 13: 439–447 [PubMed].
    [Google Scholar]
  39. Solmone M., Vincenti D., Prosperi M.C.F., Bruselles A., Ippolito G., Capobianchi M.R.. ( 2009;). Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 83: 1718–1726 [CrossRef] [PubMed].
    [Google Scholar]
  40. Standring D.N., Seifer M., Patty A., Chapron C., Van Doorn L.J., Chao G., Brown N., Lai C.L.. ( 2006;). 514 HBV resistance determination from the telbivudine globe registration trial. J Hepatol 44: (Suppl. 2), S191 [CrossRef].
    [Google Scholar]
  41. Stein L.L., Loomba R.. ( 2009;). Drug targets in hepatitis B virus infection. Infect Disord Drug Targets 9: 105–116 [CrossRef] [PubMed].
    [Google Scholar]
  42. Steinhauer D.A., de la Torre J.C., Meier E., Holland J.J.. ( 1989;). Extreme heterogeneity in populations of vesicular stomatitis virus. J Virol 63: 2072–2080,[PubMed].
    [Google Scholar]
  43. Sun J., Xie Q., Tan D., Ning Q., Niu J., Bai X., Fan R., Chen S., Cheng J., other authors. ( 2014;). The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 59: 1283–1292 [CrossRef] [PubMed].
    [Google Scholar]
  44. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., Plym M., Pokornowski K., Yu C.F., other authors. ( 2004;). Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48: 3498–3507 [CrossRef] [PubMed].
    [Google Scholar]
  45. Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R.. ( 2006;). Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439: 344–348 [CrossRef] [PubMed].
    [Google Scholar]
  46. Wain-Hobson S.. ( 1992;). Human immunodeficiency virus type 1 quasispecies in vivo and ex vivo. Curr Top Microbiol Immunol 176: 181–193 [PubMed].
    [Google Scholar]
  47. Warner N., Locarnini S., Kuiper M., Bartholomeusz A., Ayres A., Yuen L., Shaw T.. ( 2007;). The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51: 2285–2292 [CrossRef] [PubMed].
    [Google Scholar]
  48. Zoulim F., Locarnini S.. ( 2009;). Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593–1608 e1–e2. [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000285
Loading
/content/journal/jgv/10.1099/jgv.0.000285
Loading

Data & Media loading...

Supplements

Supplementary Data



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error